Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin

Exclusion Criteria

• •Females who are lactating, pregnant, or planning to become pregnant.
• •Use of any drug called a thiazolidinedione within 6 months prior to screening, or more than one oral antidiabetic agent (including combinations of agents such as Glucovance) in combination with insulin in the 3 months prior to screening.
• •Use of any investigational drug for blood glucose control within 3 months of screening regardless of the treatment regimen, or use of any other investigational agent within 30 days preceding study entry.
• •Use of niacin (not including doses found in multivitamins) or oral corticosteroids within 3 months of screening.
• •Patients with ongoing swelling due to fluid accumulation or history of such requiring treatment with a drug in the 12 months prior to screening.
• •Patients with a documented history of significant hypersensitivity (e.g., difficulty swallowing, difficulty breathing, tachycardia or skin reaction) to the drugs called thiazolidinediones or similar drugs, or with prior fluid related intolerability to thiazolidinediones.
• •Presence of clinically significant kidney or liver disease.
• •Anemia.
• •Presence of unstable or severe angina or coronary insufficiency.
• •Patients with ongoing CHF (chronic heart failure) or history of CHF.
• •Recent history or suspicion of current drug abuse or alcohol abuse.